Abstract: Calcium channel blockers are often chosen as a first-line hypotensor in the treatment of high blood pressure after organ transplantation, especially after using cyclosporine A. Calcium channel blockers and cyclosporine A are mainly metabolized by CYP450 enzyme system of liver microsomes, and both are P-glycoprotein substrates and inhibitors, so there are many interactions. The influence of different calcium channel blockers on the plasma concentration of cyclosporine A is very different. However, the immune inhibition strength, liver and kidney toxicity of cyclosporine A and it's plasma concentration are dose-dependent. Therefore it is necessary to explore the interaction of cyclosporine A and calcium channel blockers. In this paper, by analyzing the pharmacokinetic and pharmacodynamics interaction and related research progress, it is provided reasonable advice for clinical combination cyclosporine A and calcium channel blockers.